Terminated early: new drug combo tested in tough pancreatic cancer cases
NCT ID NCT06199466
Summary
This early-stage trial aimed to test the safety of a new drug, YL-13027, when given alongside two standard chemotherapy drugs (gemcitabine and nab-paclitaxel) to patients with metastatic pancreatic cancer that had stopped responding to prior treatment. The study was designed to find the safest dose and see if the combination could shrink tumors. The trial was terminated early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.